FDA authorizes Voraxaze to prevent chemo-induced toxicity

01/17/2012 | Reuters

BTG received FDA approval of Voraxaze, an injectable medicine that breaks down chemotherapy agent methotrexate to prevent kidney failure and other side effects of prolonged exposure. During a study, 10 of 22 patients had a low concentration of methotrexate in their blood within 15 minutes of taking Voraxaze, and the effect was sustained for eight days, the FDA said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care